Small Cell Lung Cancer
When can surgery be considered?

• ◆Surgery is not standard treatment for small cell lung cancer, and most people with this diagnosis will be treated with chemotherapy and radiotherapy rather than an operation.
• ◆NICE allows surgery to be considered in early-stage disease staged T1 to 2a, N0, M0; ESMO allows it in cT1-2N0 after multidisciplinary decision, and requires pathological mediastinal staging first.
• ◆The operation is an anatomical resection, usually lobectomy, with systematic nodal dissection. A wedge resection is not the standard approach to confirmed small cell lung cancer.
• ◆Small cell is sometimes found only on the resection specimen, after an operation planned for something else. That changes the treatment plan, not the value of the operation.
• ◆An EGFR-mutant lung cancer can transform into small cell during targeted treatment. Confirming that requires new tissue, because it is a diagnosis made under a microscope.

Can small cell lung cancer
be treated with surgery?

For most people who receive this diagnosis, the honest answer is no, and it is worth saying that at the outset rather than at the end. Small cell lung cancer is a high-grade neuroendocrine cancer that grows quickly and spreads through the bloodstream early. That biology is the reason chemotherapy and radiotherapy became the treatment: they act everywhere at once, and an operation does not. Roughly two-thirds of people have disease that has already spread beyond the chest by the time it is found.

But “not standard” is not the same as “never”, and the guidelines are clearer on this than most patient information suggests. NICE states that surgery should be considered in people with early-stage small cell lung cancer staged T1 to 2a, N0, M0. The European Society for Medical Oncology states that surgery may be considered in clinical stage I and II disease, specifically cT1-2N0, following a multidisciplinary board decision, with pathological mediastinal staging required and adjuvant chemotherapy given afterwards.

Approximately 5% of people with small cell lung cancer present with disease in that category. It is a small door, but it is a real one, and it is open by guideline rather than by exception. The purpose of this page is to describe precisely who stands in front of it — and to be equally precise about who does not.

There is a second group this page addresses, and it is the one most often left out. Some people are not identified as having small cell lung cancer before an operation at all. They have a lung nodule, the imaging suggests an early non-small cell cancer or is simply indeterminate, an operation is performed — and the small cell is found afterwards, on the specimen. That situation has its own answers, and they are set out further down.

What do limited stage and
extensive stage mean?

Most people diagnosed with small cell lung cancer are told they have either limited-stage or extensive-stage disease, rather than a stage number. This is a genuine difference from the way other lung cancers are described, and it causes a lot of confusion when patients then read about stage I or T1N0 elsewhere.

Limited stage broadly means the cancer is confined to one side of the chest and can be encompassed within a single radiotherapy field. Extensive stage means it has spread beyond that — to the other lung, to the pleura, or to organs outside the chest. Around a third of people have limited-stage disease at diagnosis. The distinction exists because it was, historically, the decision that mattered: whether treatment could be given with curative intent.

Small cell lung cancer is also staged by the same TNM system used for other lung cancers, and both descriptions are usually recorded. That matters here because the surgical question lives inside the TNM description, not the limited/extensive one. Limited stage is a large group; the surgical subset within it is small. Someone can have limited-stage disease, be treated with curative intent, and still have no surgical option — because the lymph nodes are involved, or the tumour is central, or its size places it outside what the guidelines permit.

So if you have been told “limited stage” and are wondering why surgery has not been mentioned, the answer is usually not that it was overlooked. It is that limited stage and operable are different things, and the second is a much narrower category than the first.

Who is eligible for
small cell lung cancer surgery?

The eligible group is defined by four things at once, and all four have to hold.

The tumour must be confined to the lung, and small. There must be no involvement of the hilar or mediastinal lymph nodes — and that has to be proved rather than inferred. There must be no evidence of spread elsewhere, including the brain. And the person must be fit enough for an anatomical lung resection, which is a larger operation than a diagnostic biopsy and demands a corresponding reserve of lung function.

The two guidelines that govern UK practice express the threshold slightly differently, and the difference is worth knowing about. NICE says T1 to 2a. ESMO says cT1-2. Those are not identical populations, and there is a further wrinkle: the NICE recommendation carries a 2011 date stamp and was written using the seventh edition of the staging system, which NICE itself flags. The staging system has since moved on. A patient staged today is described in a vocabulary that postdates the recommendation being applied to them.

None of that is a reason to widen the criteria unilaterally. It is a reason for the decision to be made in a multidisciplinary meeting, with a surgeon in the room who understands what the staging actually shows, rather than by mechanical application of a threshold. If you have been told surgery is not possible and you are not sure the staging was complete, that is a reasonable thing to ask about — and a reasonable reason to seek a second surgical opinion.

What staging is needed
before the decision?

More than for most cancers, and for a specific reason: in small cell lung cancer the consequence of understaging is not a slightly worse operation, it is the wrong treatment strategy altogether.

The baseline is contrast-enhanced CT of the chest and abdomen, PET-CT, and dedicated brain imaging. Brain imaging is not optional here in the way it sometimes is elsewhere; small cell lung cancer reaches the brain frequently and early, and finding that before an operation rather than after it changes everything. The full sequence of tests and what each one answers is set out separately.

Beyond imaging, ESMO requires pathological mediastinal staging before resection is considered. That means tissue from the mediastinal lymph nodes, not a radiologist’s assessment of their size or their appearance on PET. In practice this is achieved by endobronchial ultrasound (EBUS), endoscopic ultrasound (EUS), or surgical staging, and which of those is appropriate depends on which nodal stations are in question.

The reason for the requirement is straightforward. Nodal disease that is invisible on imaging is common, and it is not a theoretical concern. In a consecutive series of small cell lung cancer resections at Guy’s Hospital that Dr Okiror reported, six of fifteen patients were found to have involved lymph nodes on the final pathology — five with hilar and one with mediastinal involvement — despite preoperative CT, PET and selective EBUS. That is a small series and a descriptive observation rather than a rate. But it makes the guideline’s insistence on pathological staging concrete rather than procedural.

Where a peripheral lesion also needs a tissue diagnosis, ION robotic bronchoscopy can reach nodules in the outer lung that conventional bronchoscopy cannot, and can be combined with EBUS nodal sampling in the same anaesthetic. The point is not the technology. The point is that the diagnosis and the nodal status are both settled before a decision about resection is taken, rather than after.

What operation is performed,
and what follows it?

The principle is anatomical complete resection. In practice that usually means a lobectomy — removal of the affected lobe of the lung — together with systematic dissection of the mediastinal lymph nodes. The nodal dissection is not an optional extra; it is how the pathological stage is established, and the pathological stage is what determines the rest of the treatment.

A wedge resection or other limited resection is not the standard surgical approach to confirmed small cell lung cancer. This is a real difference from early non-small cell lung cancer, where two large randomised trials have established segmentectomy as equivalent to lobectomy for small peripheral tumours. That evidence does not transfer across histologies, and it should not be assumed to.

Where the anatomy allows, the resection can usually be performed by robotic or keyhole technique rather than open thoracotomy, with the recovery advantages that brings. But the extent of the operation is dictated by the cancer, not by the method of access, and the sequence matters: the histology and the nodal status determine what operation is right, and the approach is chosen afterwards.

Some patients are offered chemotherapy first, with surgery planned afterwards. If that is the sequence you have been given, it is a recognised approach rather than an error — the intention is to treat any disease that has already left the lung, and to see how the tumour behaves before committing to an operation. It is worth knowing that this was the exact strategy tested by the Lung Cancer Study Group trial in 1994, in patients with nodal disease, and that the trial did not show a survival advantage over radiotherapy. Where induction chemotherapy is used today it is generally in more selected circumstances, and the decision belongs to the multidisciplinary team rather than to any single specialty. If it has been proposed for you, the question worth asking is what the plan becomes if the restaging scan after chemotherapy shows something different from what was expected.

Surgery is not the whole treatment, and this is the single most important thing to understand about the surgical pathway in small cell lung cancer. ESMO recommends adjuvant chemotherapy after resection, with cisplatin and etoposide the preferred regimen in limited-stage disease, unless there is a specific reason it cannot be given. Concurrent thoracic radiotherapy is recommended where the resection was incomplete or where mediastinal nodal involvement is found. Prophylactic cranial irradiation is considered separately. These are oncology decisions taken by the multidisciplinary team once the pathology is known, and an operation that is not followed by systemic treatment has not delivered what it was intended to deliver.

Why was surgery abandoned,
and why has the question returned?

Surgery was not abandoned in small cell lung cancer by drift or fashion. It lost a randomised comparison, and the profession accepted the result. Understanding what those trials actually tested is the key to understanding why a narrow surgical option survives in the guidelines today.

1973 · The Medical Research Council trial

Fox and Scadding reported the ten-year follow-up of a Medical Research Council trial comparing surgery with radical radiotherapy. Seventy-one patients were allocated to surgery, and complete resection was achieved in thirty-four of them. Radiotherapy performed better, and surgery fell out of use. The trial predates CT staging, PET-CT, endobronchial ultrasound and every modern chemotherapy regimen, and most of its patients were diagnosed bronchoscopically, meaning central tumours predominated.

1994 · The Lung Cancer Study Group

Lad and colleagues randomised patients who had responded to induction chemotherapy to surgical resection of residual disease or to radiotherapy. Two-year survival was equivalent in both arms, and surgery was again not recommended. But the trial asked a different question from the one the guidelines now permit: its patients had regional nodal disease, not the node-negative tumour that NICE and ESMO describe.

2017 · What the Cochrane review concluded

A Cochrane systematic review (Barnes and colleagues, 2017) found three randomised trials, 330 participants in total, and judged the quality of evidence very low for every outcome. The trials were too different to combine. The review concluded that the available randomised evidence does not support surgical resection in limited-stage small cell lung cancer — and then added the sentence that matters most: that its conclusions may not be generalisable to patients with clinical stage 1 disease carefully staged using contemporary staging methods, and that prospective randomised trials are needed.

That is the honest position. The randomised evidence against surgery is real, and it is old, and it was generated in a population that is not the population the guidelines now describe. The node-negative, PET-staged, EBUS-confirmed patient of 2026 was, in effect, never randomised.

2021–2026 · What has changed, and what has not

ESMO’s 2021 guideline set out the current position: surgery may be considered in cT1-2N0 after a multidisciplinary decision, with pathological mediastinal staging and adjuvant chemotherapy. Since then, observational series have reported favourable outcomes in selected surgical patients, including a single-centre cohort published in Lung Cancer in August 2026 (Roesch and colleagues) comparing 115 patients who underwent resection with 115 treated by definitive chemoradiotherapy over the same period.

Those studies show that surgery is being used, and reported, more often in selected early-stage disease. They do not show that surgery causes the better outcomes, and their authors are careful to say so — the 2026 cohort describes its own findings as hypothesis-generating and subject to residual selection bias. The reason for that caution is worth stating plainly: a surgical cohort is staged on the resected specimen with the nodes dissected, while a chemoradiotherapy cohort is staged on imaging. Matching two such groups on stage matches the label, not necessarily the disease.

The position that survives all of this is narrow and defensible. Surgery has a role in a small, rigorously staged group, as part of multimodality treatment. It is not a general option in small cell lung cancer, and no honest reading of the evidence makes it one.

What happens if small cell is
found unexpectedly after surgery?

Sometimes the diagnosis is made only after the operation. This is a recognised clinical situation rather than a mishap, and if it has happened to you it is worth understanding how it happens.

A lung nodule is found, often incidentally or through screening. The imaging suggests an early non-small cell cancer, or is simply indeterminate. A biopsy may not be technically possible, may not be attempted because the appearances are convincing enough, or may be performed and return a result that is not the whole story. The nodule is resected. And the final pathology, examined properly across the whole specimen rather than a needle core, shows small cell lung cancer — or a combined tumour containing both small cell and non-small cell components.

What changes at that point is the treatment plan, not the value of what has already been done. The case returns to the multidisciplinary meeting. Systemic chemotherapy becomes part of treatment. Radiotherapy is considered according to the margins and the nodal findings. The pathological staging obtained from the systematic nodal dissection becomes the foundation of every subsequent decision — which is one of the reasons a proper nodal dissection matters even when the surgeon believes the diagnosis is something else.

There is now published evidence specifically on this group. Guo and colleagues reported 120 patients with postoperative unsuspected small cell lung cancer treated at a single centre between 2000 and 2021, and found outcomes that support treating these patients on a curative pathway with surgery followed by adjuvant therapy, with lobectomy and systematic lymph node dissection recommended. That is a retrospective series from one institution, and it does not settle the question of whether these patients would have done as well without the operation. But it does mean that an unexpected small cell result is a recognised pathway with a literature behind it, not an orphan situation.

If small cell has been reported on your resection specimen and you are unclear what it means for the rest of your treatment, that is a specific and answerable question, and one worth asking a thoracic surgeon rather than working out alone.

What is combined small cell and
non-small cell lung cancer?

A combined tumour contains both a small cell component and a non-small cell component — most often adenocarcinoma or squamous cell carcinoma — within the same cancer. It is not a diagnostic error and it is not a borderline call. It is a recognised entity, and it is one of the reasons a needle biopsy of a lung tumour cannot always be taken as the final word.

The practical problem is one of sampling. A needle passes through a small part of a tumour. If the small cell component occupies a different region from the part sampled, the biopsy will report whatever it happened to encounter. In the Guy’s series described above, three of the four patients whose preoperative biopsy was reported as non-small cell turned out to have combined tumours when the whole specimen was examined — two combined small cell and adenocarcinoma, one combined small cell and squamous cell.

Small cell can also be combined with large cell neuroendocrine carcinoma (LCNEC), which is a separate high-grade neuroendocrine cancer of the lung rather than a form of small cell. Combined small cell and LCNEC tumours are uncommon and there is correspondingly little written about them, which is why patients and families who receive this diagnosis often struggle to find anything useful. In practice the small cell component generally governs the treatment approach, and the case is managed through the multidisciplinary meeting on that basis. The scarcity of literature reflects how rarely these tumours occur, not a gap in how they are treated.

Once a combined tumour is identified, the small cell component drives the treatment. That means systemic chemotherapy on small cell principles, with the multidisciplinary team deciding on radiotherapy according to the pathology. The practical consequence for anyone reading a biopsy report is a modest one but worth holding onto: a needle biopsy reporting non-small cell carcinoma establishes what was in the needle. The resection specimen establishes what was in the tumour.

Can EGFR-mutant lung cancer
change into small cell lung cancer?

Yes, and this is a situation that arises in a quite different group of people from everything above. The person here is usually being treated for advanced EGFR-mutant lung adenocarcinoma, often a never-smoker, often younger than the typical lung cancer patient, doing well on a targeted tablet — and then the disease starts behaving differently from the pattern their team expected.

Between 3% and 10% of EGFR-mutant non-small cell lung cancers undergo transformation to small cell lung cancer. The largest published series is that of Marcoux and colleagues in the Journal of Clinical Oncology in 2019, which assembled 67 patients across eight institutions. The median time from initial diagnosis to transformation was 17.8 months. The transformed tumours kept their original EGFR mutation, which is part of what establishes that this is the same cancer changing rather than a second, unrelated one appearing. Recurrent alterations in TP53 and RB1 were common; concurrent loss of both has since been described as marking a subset of EGFR-mutant lung cancers at particular risk of histological transformation (Offin and colleagues, Journal of Thoracic Oncology, 2019).

Why this matters practically: transformation is a change in what the cancer is, not simply the cancer growing again. The treatment that follows is different — platinum-etoposide chemotherapy rather than another targeted agent. In the Marcoux series, none of the seventeen patients treated with immunotherapy after transformation responded. Assuming ordinary progression and reaching for the next line of targeted treatment can therefore mean months of treatment aimed at a cancer that no longer exists in that form.

The reason this connects to a surgical page is tissue. Transformation is a morphological diagnosis: a pathologist looks down a microscope and sees small cell. A blood test can raise the suspicion — the emergence of new alterations in circulating tumour DNA, for instance — but it cannot make the diagnosis, because the diagnosis is a description of what the cells look like. If the clinical behaviour suggests transformation, obtaining new tissue from the active disease is what settles it.

Where new tissue is needed, the right biopsy route depends on where the active disease sits. Some lesions are straightforward percutaneously. Others are small, deep in the outer lung, or in an area of previously treated lung where a needle through the chest wall is unattractive. In those cases the airway may be the better route: ION robotic bronchoscopy navigates to peripheral lesions through the bronchial tree, with cone-beam CT confirming position before any sample is taken. The objective is not simply to prove that cancer is present again. It is to obtain enough tissue to establish what the cancer has become.

Does small cell lung cancer
always come back after treatment?

No — and this is worth stating plainly, because the belief that it always returns is widespread and it is not accurate for limited-stage disease.

Small cell lung cancer does have a high recurrence rate, and it is honest to say so. Relapse after an initially good response is common, and it is the reason surveillance after treatment is close and the reason systemic treatment is given even when the disease appeared confined. None of that is in dispute. But limited-stage small cell lung cancer is treated with curative intent, that intent is not a formality, and some people are cured. Long-term survivors exist, including people who completed treatment for limited-stage disease years ago and never saw the cancer return.

After a resection, surveillance is generally more frequent than after surgery for non-small cell lung cancer, with imaging at short intervals in the first years and then lengthening if things remain stable. The intensity reflects the biology, not pessimism about any individual. Your oncology team sets the schedule; the practical point for anyone recovering from an operation is that frequent scanning is the expected pattern and is not a sign that something has been found.

Prophylactic cranial irradiation — sometimes described to patients as preventative cranial irradiation, or PCI — is considered separately after treatment for limited-stage disease. It is directed at the brain, where small cell lung cancer commonly spreads, and is intended to reduce that risk before anything is visible. Whether it is offered depends on the response to treatment and on individual factors, and it is an oncology decision.

If the cancer does return, that is not the end of treatment. Further systemic options exist and the field is moving, and a recurrence is a reason to go back to the multidisciplinary team rather than to conclude that nothing more can be done.

When is surgery not
the right treatment?

Most of the time. It is worth being explicit about the circumstances, because a page describing a narrow surgical option can easily be read as offering more than it does.

Surgery is not appropriate where lymph nodes are involved. Nodal disease changes the treatment strategy rather than simply extending the operation, and chemoradiotherapy is what addresses it. It is not appropriate where disease has spread beyond the chest, which is the situation for around two-thirds of people at diagnosis. It is not appropriate for tumours that are large, central, or involving structures that cannot be cleared with a complete resection. And it is not appropriate where lung function or general fitness cannot support an anatomical resection — though fitness is more often assessable than assumed, and is a question worth putting properly rather than answering by impression.

There is also a group for whom definitive chemoradiotherapy is simply the better treatment, not the consolation prize. Concurrent chemoradiotherapy is the established standard of care in limited-stage small cell lung cancer, and it is a curative-intent treatment. Being told that surgery is not part of your plan is not being told that cure is off the table.

If your team has recommended chemotherapy and radiotherapy, that recommendation is very likely correct, and this page should not be read as a reason to doubt it. The circumstances in which a surgical opinion adds something are narrower: where the disease appears genuinely localised and node-negative and you are unsure whether pathological mediastinal staging was performed; where small cell has been found on a resection specimen; or where an EGFR-mutant cancer is behaving in a way that raises the question of transformation.

References

1. National Institute for Health and Care Excellence. Lung cancer: diagnosis and management. NICE guideline NG122, 2019 (recommendation dated 2011).
2. Dingemans A-MC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32(7):839–853.
3. Barnes H, See K, Barnett S, Manser R. Surgery for limited-stage small-cell lung cancer. Cochrane Database Syst Rev 2017;4:CD011917. PMID 28429473.
4. Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet 1973;2:63–65.
5. Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994;106:320S–323S.
6. Okiror L, Karenovics W, Billè A, et al. Contemporary single institution experience in the surgical treatment of patients with small cell lung cancer. Lung Cancer 2013;79(1):S73, abstract 212. doi:10.1016/S0169-5002(13)70212-5.
7. Guo J, Shen L, Ren Z, Liu Y, Liang C. Long-term results of postoperative unsuspected small cell lung cancer on real-world data. BMC Cancer 2022;22(1):1256. PMID 36461029.
8. Marcoux N, Gettinger SN, O’Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol 2019;37(4):278–285. PMID 30550363.
9. Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol 2019;14(10):1784–1793.
10. Roesch RM, Utz M, Eichhorn F, Christopoulos P, Brendel L, Griffo R, Muley T, Schneider MA, Shi S, Herth F, Niedermaier B, Thomas M, Eichhorn ME, Winter H, Klotz LV. Reassessing surgical resection in small cell lung cancer in the multimodal treatment era. Lung Cancer 2026; article 109600, in press, published online 30 August 2026. PII S0169-5002(26)00661-6.

A clear answer on whether
surgery has a role.

Self-referrals welcome. Dr Okiror reviews scans, pathology and staging personally, and will say plainly where surgery has no part to play. Consultations at London Bridge Hospital and The Lister Hospital Chelsea are usually available within 2–3 working days, with virtual review often possible within 24 hours.